The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms

Key words

pimavanserin - antipsychotic - psychosis - schizophrenia - hallucinogen

Publication History

Article published online:
11 July 2022

• References

• 1 Cusick E, Gupta V. Pimavanserin. In: StatPearls. Treasure Island (FL). 2022
• 2 Howland RH. Pimavanserin: An Inverse Agonist Antipsychotic Drug. J Psychosoc Nurs Ment Health Serv 2016; 54: 21-24
• 3 Jalal B. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl) 2018; 235: 3083-3091
• 4 Litjens RP, Brunt TM, Alderliefste GJ. et al. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol 2014; 24: 1309-1323
• 5 American Psychiatric A.. Diagnostic and Statistical Manual of Mental Disorders 2013;
• 6 Martinotti G, Santacroce R, Pettorruso M. et al. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sci 2018; 8
• 7 Alcantara AG. Is there a role for the alpha2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone?. J Clin Psychopharmacol 1998; 18: 487-488
• 8 Lev-Ran S, Feingold D, Frenkel A. et al. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. J Dual Diagn 2014; 10: 79-83
• 9 Lev-Ran S, Feingold D, Rudinski D. et al. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation. Am J Addict 2015; 24: 197-199
• 10 Nutting S, Bruinsma T, Anderson M. et al. Psychotic and Still Tripping – Hallucinogen Persisting Perception Disorder and First Break Psychosis in an Adolescent. Int J Ment Health Addict 2020; 19: 2440-2442